[go: up one dir, main page]

FI20011671A7 - Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö - Google Patents

Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö Download PDF

Info

Publication number
FI20011671A7
FI20011671A7 FI20011671A FI20011671A FI20011671A7 FI 20011671 A7 FI20011671 A7 FI 20011671A7 FI 20011671 A FI20011671 A FI 20011671A FI 20011671 A FI20011671 A FI 20011671A FI 20011671 A7 FI20011671 A7 FI 20011671A7
Authority
FI
Finland
Prior art keywords
oligosaccharide sequences
present
tumor
oligosaccharide
agents
Prior art date
Application number
FI20011671A
Other languages
English (en)
Swedish (sv)
Other versions
FI20011671L (fi
FI20011671A0 (fi
Inventor
Karl-Anders Karlsson
Susann Teneberg
Jari Natunen
Original Assignee
Carbion Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carbion Oy filed Critical Carbion Oy
Priority to FI20011671A priority Critical patent/FI20011671L/fi
Publication of FI20011671A0 publication Critical patent/FI20011671A0/fi
Priority to US10/487,203 priority patent/US8236487B2/en
Priority to EP02753102.9A priority patent/EP1419393B1/en
Priority to JP2003521371A priority patent/JP2005500535A/ja
Priority to PCT/FI2002/000681 priority patent/WO2003016915A1/en
Publication of FI20011671A7 publication Critical patent/FI20011671A7/fi
Publication of FI20011671L publication Critical patent/FI20011671L/fi
Priority to DK03792440.4T priority patent/DK1534324T3/en
Priority to US10/525,011 priority patent/US8697061B2/en
Priority to US14/223,346 priority patent/US20140234318A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G01N33/5756—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Esillä oleva keksintö kuvaa oligosakkaridisekvenssejä, joita ihmisen tuumorit spesifisesti ilmentävät. Esillä oleva keksintö liittyy tuumorispesifisen terminaalisen N-asetyyliglukosamiinitähteen sisältävän oligosakkaridisekvenssin määritysmenetelmään biologisessa näytteessä, mainitun sekvenssin läsnäolon mainitussa näytteessä ollessa osoitus syövän läsnäolosta. Esillä oleva keksintö antaa käyttöön antigeenisiä aineita, jotka sisältävät mainittuja oligosakkaridisekvenssejä polyvalentissa muodossa ja lisäksi se antaa käyttöön diagnostisia aineita, farmaseuttisia koostumuksia ja syöpärokotteita, jotka sisältävät mainittuja oligosakkaridisekvenssejä tai mainittuihin oligosakkaridisekvensseihin sitoutuvia aineita. Esillä oleva keksintö liittyy myös menetelmiin syövän hoitamiseksi.
FI20011671A 2001-08-20 2001-08-20 Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö FI20011671L (fi)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FI20011671A FI20011671L (fi) 2001-08-20 2001-08-20 Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
US10/487,203 US8236487B2 (en) 2001-08-20 2002-08-20 Tumor specific oligosaccharide sequences and use thereof
EP02753102.9A EP1419393B1 (en) 2001-08-20 2002-08-20 Tumor specific oligosaccharide sequences and use thereof
JP2003521371A JP2005500535A (ja) 2001-08-20 2002-08-20 腫瘍特異的オリゴ糖配列およびその用途
PCT/FI2002/000681 WO2003016915A1 (en) 2001-08-20 2002-08-20 Tumor specific oligosaccharide sequences and use thereof
DK03792440.4T DK1534324T3 (en) 2001-08-20 2003-08-20 TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF
US10/525,011 US8697061B2 (en) 2001-08-20 2003-08-20 Tumor specific oligosaccharide epitopes and use thereof
US14/223,346 US20140234318A1 (en) 2001-08-20 2014-03-24 Tumor specific oligosaccharide epitopes and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20011671A FI20011671L (fi) 2001-08-20 2001-08-20 Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö

Publications (3)

Publication Number Publication Date
FI20011671A0 FI20011671A0 (fi) 2001-08-20
FI20011671A7 true FI20011671A7 (fi) 2003-02-21
FI20011671L FI20011671L (fi) 2003-02-21

Family

ID=8561761

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20011671A FI20011671L (fi) 2001-08-20 2001-08-20 Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö

Country Status (6)

Country Link
US (3) US8236487B2 (fi)
EP (1) EP1419393B1 (fi)
JP (1) JP2005500535A (fi)
DK (1) DK1534324T3 (fi)
FI (1) FI20011671L (fi)
WO (1) WO2003016915A1 (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011671L (fi) 2001-08-20 2003-02-21 Carbion Oy Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
EP1534324B1 (en) * 2002-08-20 2019-01-16 Glykos Finland Oy Tumor specific oligosaccharide epitopes and use thereof
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
US8759005B2 (en) * 2005-07-11 2014-06-24 Glykos Finland Oy Tissue carbohydrate compositions and analysis thereof
WO2007006870A2 (en) * 2005-07-11 2007-01-18 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
FI20055417A0 (fi) * 2005-07-20 2005-07-20 Glykos Finland Oy Syöpäpesifiset glykaanit ja niiden käyttö
EP2623609B1 (en) 2006-02-10 2017-01-04 Life Technologies Corporation Labeling and detection of post translationally modified proteins
FI20075030A0 (fi) 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Menetelmä solujen modifioimiseksi
EP2115460A4 (en) 2007-01-18 2010-01-13 Suomen Punainen Risti Veripalv NEW CARBOHYDRATE FROM HUMAN CELLS AND METHOD FOR THE ANALYSIS AND MODIFICATION THEREOF
JP2010516239A (ja) 2007-01-18 2010-05-20 スオメン プナイネン リスティ，ヴェリパルベル 細胞の産生に対する新規方法および試薬
US20100047827A1 (en) 2007-01-18 2010-02-25 Suomen Punainen Risti, Veripalvelu Novel specific cell binders
US20080318332A1 (en) * 2007-05-29 2008-12-25 Mechref Yehia S Disease diagnosis by profiling serum glycans
EP2166085A1 (en) * 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
WO2013154751A1 (en) * 2012-04-10 2013-10-17 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Methods for analyzing glycan-derived monosaccharides
HUE038285T2 (hu) 2012-10-23 2018-10-29 Synaffix Bv Módosított antitest, antitest-konjugátum és eljárás ezek elõállítására
WO2015120362A1 (en) * 2014-02-10 2015-08-13 Albert Einstein College Of Medicine Of Yeshiva University Methods of grading carcinomas
JP2017528124A (ja) 2014-08-04 2017-09-28 シンアフィックス ビー．ブイ． ベータ−（１，４）−ｎ−アセチルガラクトサミニルトランスフェラーゼ又はその突然変異体を用いる糖タンパク質の改変方法
EP3134520B1 (en) 2015-04-23 2017-12-20 Synaffix B.V. Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a (1,4)-n-acetylgalactosaminyltransferase
WO2017011728A1 (en) * 2015-07-15 2017-01-19 Washington University ANTIBODIES TO TUMOR ASSOCIATED COMPLEX N-GLYCANS WITH TERMINAL GlcNAcBeta RESIDUES AND METHODS OF USE THEREOF
US20220241311A1 (en) * 2018-06-14 2022-08-04 Mayo Foundation For Medical Education And Research Methods and materials for treating glycosylation disorders
US11506664B1 (en) * 2021-04-23 2022-11-22 Academia Sinica Methods for detecting and treating cholangiocarcinoma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618443D0 (en) * 1986-07-29 1986-09-03 Univ London Monoclonal antibodies
JP2579497B2 (ja) 1987-09-07 1997-02-05 オリエンタル酵母工業株式会社 肝臓疾患診断剤
GB8726271D0 (en) * 1987-11-10 1987-12-16 Univ London Protein glycosylation assay
DE3807594A1 (de) 1988-03-08 1989-09-21 Reutter Werner Antikoerper, verfahren zu ihrer herstellung, oligosaccharid-haptene und klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren
CA1313496C (en) * 1988-04-29 1993-02-09 James Wilson Dennis Diagnostic method to screen tumors
JPH02264864A (ja) * 1989-04-04 1990-10-29 Shin Etsu Chem Co Ltd Ｇｓａ―２結合性蛋白質の免疫学的測定試薬及びそれを用いた免疫学測定用キット
DE4009630C2 (de) 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US6075134A (en) * 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
AU1443900A (en) * 1998-10-09 2000-05-01 University Technology Corporation Glycoprotein antigens, antibodies specific thereto and method for producing same
JP4351314B2 (ja) * 1998-12-24 2009-10-28 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
GB0012216D0 (en) 2000-05-19 2000-07-12 European Molecular Biology Lab Embl Glycosyltransferase protein
FI20010118L (fi) 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
FI20011664L (fi) * 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
FI20011671L (fi) 2001-08-20 2003-02-21 Carbion Oy Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2006068758A2 (en) 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
US20070265170A1 (en) 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer

Also Published As

Publication number Publication date
US8236487B2 (en) 2012-08-07
US20050014718A1 (en) 2005-01-20
US8697061B2 (en) 2014-04-15
EP1419393B1 (en) 2014-08-13
WO2003016915A8 (en) 2004-02-05
JP2005500535A (ja) 2005-01-06
FI20011671L (fi) 2003-02-21
US20060014672A1 (en) 2006-01-19
EP1419393A1 (en) 2004-05-19
FI20011671A0 (fi) 2001-08-20
US20140234318A1 (en) 2014-08-21
WO2003016915A1 (en) 2003-02-27
DK1534324T3 (en) 2019-04-08

Similar Documents

Publication Publication Date Title
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
ATE330967T1 (de) An her2 bindende peptidverbindungen
BRPI0412567A (pt) anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
DE60130468D1 (de) Zusammensetzungen und verfahren zur behandlung von chlamydia-infektionen
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
DE60229059D1 (de) Proteomimetische verbindungen und verfahren
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2004046332A3 (en) Amplified genes involved in cancer
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
EP2322209A3 (en) Tumor specific oligosaccharide epitopes and use thereof
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
GB0324656D0 (en) A protein involved in ovarian cancer
EA200600995A1 (ru) Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
ATE505538T1 (de) Dna-vektoren

Legal Events

Date Code Title Description
MA Patent expired